{ "schema_version": "1.0", "generated_on": "2026-09-03", "source_checked_on": "2026-09-03", "records": [ { "record_id": "SRC-FDA-DDM-2026-08-20", "title": "FDA sets out fit-for-purpose considerations for digitally derived measures in clinical investigations", "record_type": "Official FDA measurement-science paper", "canonical_route": "/source-watch/#fda-ddm", "source_authority": "U.S. Food and Drug Administration", "source_url": "https://www.fda.gov/medical-devices/digital-health-center-excellence/key-considerations-development-and-use-digitally-derived-measures-clinical-investigations-fda-paper", "source_document_url": "https://www.fda.gov/media/194348/download", "source_published_on": "2026-08-20", "freshness": "Current", "status": "Published FDA paper", "evidence_tracks": [ "Measures and endpoints", "Technologies and care models", "Implementation and adoption" ], "source_facts": [ "FDA's medical-product centers jointly published a paper drawing key considerations from existing FDA guidances for the development and use of digitally derived measures as outcomes in clinical investigations.", "FDA describes digitally derived measures as measures derived from data collected using digital health technologies.", "The paper says a digitally derived measure may be used as a clinical outcome assessment, biomarker, or part of a multicomponent endpoint derived from multimodal data.", "For a digital health technology used to generate a digitally derived measure in a clinical investigation, FDA identifies verification, analytical and clinical validation, usability and human factors, clinically relevant and patient-meaningful concepts, and potential sources of error as key considerations." ], "limits": [ "The paper synthesizes considerations from existing FDA guidances; it does not qualify or validate a particular measure, endpoint, digital health technology, product, or claim.", "Fit for purpose depends on the proposed context of use and the evidence supporting selection, relevance, validity, usability, and error control.", "Publication does not establish safety, effectiveness, regulatory authorization, coverage, reimbursement, or adoption for a specific technology or intervention." ], "p4l_interpretation": "A digitally derived measure should be treated as a decision object with an explicit concept of interest, context of use, patient relevance, verification and validation evidence, usability evidence, error model, and change-control plan—not as a sensor output that becomes an endpoint by default.", "decision_use": "Use the FDA paper as a source-linked screening framework when deciding whether a proposed digital measure is ready to support a clinical investigation, while consulting the applicable FDA guidances and FDA as appropriate for the specific context.", "watch_conditions": [ "New or revised FDA guidance cited by the paper", "Regulatory examples clarifying context-specific endpoint acceptance", "Validation and usability evidence for proposed measures", "Software, algorithm, or device changes that may alter measurement performance" ], "dependent_views": [ "/source-watch/", "/public-references/ddm-decision-brief/", "/public-references/healthspan-evidence-map/", "/data/v2/query-index.json" ], "publication_date_basis": "FDA CDRH update log entry", "publication_date_basis_url": "https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrh-new-news-and-updates" }, { "record_id": "SRC-FDA-DD-ENDPOINTS-WORKSHOP-2026-08-27", "title": "FDA workshop examines statistical considerations for digitally derived endpoints", "record_type": "Official FDA/Duke-Margolis convening record", "canonical_route": "/source-watch/#fda-workshop", "source_authority": "U.S. Food and Drug Administration and Duke-Margolis Institute for Health Policy", "source_urls": [ "https://www.fda.gov/drugs/news-events-human-drugs/fda-virtual-workshop-digital-health-technologies-and-statistical-considerations-digitally-derived", "https://healthpolicy.duke.edu/events/statistical-considerations-digitally-derived-endpoints-clinical-trials", "https://healthpolicy.duke.edu/sites/default/files/2026-08/Agenda_Digitally%20Derived%20Endpoints_8.25.26.pdf", "https://healthpolicy.duke.edu/sites/default/files/2026-08/Speaker%20Biosheet_Digitally%20Derived%20Endpoints.pdf", "https://healthpolicy.duke.edu/sites/default/files/2026-09/Slide%20Deck%20Digitally%20Derived%20Endpoints.pdf", "https://www.youtube.com/watch?v=w7X3l69iroc" ], "event_date": "2026-08-27", "freshness": "Current", "status": "Completed event · post-event materials available · P4L review pending", "evidence_tracks": [ "Measures and endpoints", "Science and market landscape" ], "source_facts": [ "FDA's event page and the Duke-Margolis convening page document an August 27, 2026 virtual public workshop convened by Duke-Margolis under a cooperative agreement with FDA.", "The posted agenda covers regulatory efforts, continuous glucose monitoring technical specifications, measurement and validation, data provenance, missing data, statistical analysis, and future considerations for digitally derived endpoints.", "The Duke-Margolis page provides the agenda, speaker biographies, a 192-page event slide deck, and an embedded recording of the completed workshop." ], "limits": [ "The event page and agenda describe speakers, objectives, and discussion questions; they are not themselves consensus findings or new FDA guidance.", "The Duke-Margolis funding acknowledgment says the materials do not necessarily represent official FDA or HHS views or endorsement.", "P4L has not treated remarks in the recording as an FDA policy position or endpoint-acceptance decision.", "Any detailed synthesis of presentations or discussion requires speaker-level attribution and review against the posted materials." ], "p4l_interpretation": "The completed workshop supplies a useful post-event evidence set for questions about validation, missingness, data provenance, standardization, and intended regulatory use. Those materials should be reviewed with speaker-level attribution before any conclusion is generalized.", "decision_use": "Use the source set to identify issues for a digitally derived endpoint evidence plan. Continue to rely on applicable FDA guidance and product-specific agency engagement for regulatory decisions.", "watch_conditions": [ "Publication of additional slides, transcript, proceedings, or technical materials", "Subsequent FDA guidance or specifications on digitally derived endpoints", "Updated continuous glucose monitoring technical specifications", "Examples connecting workshop topics to regulatory decisions" ], "dependent_views": [ "/source-watch/", "/public-references/ddm-decision-brief/", "/data/v2/query-index.json" ] }, { "record_id": "SRC-XPRIZE-HEALTHSPAN-2026-08-11", "title": "XPRIZE Healthspan advances 20 finalist teams; 10 receive $1 million milestone awards", "record_type": "Official competition milestone announcement", "canonical_route": "/source-watch/#xprize-healthspan", "source_authority": "XPRIZE Foundation", "source_url": "https://www.xprize.org/news/10-finalist-teams-awarded-1m-to-advance-in-xprize-healthspan-101-million-race-to-transform-healthy-aging", "source_urls": [ "https://www.xprize.org/competitions/healthspan", "https://www.xprize.org/news/20-healthspan-finalist-teams-advance-in-the-race-to-extend-healthy-aging", "https://www.xprize.org/news/10-finalist-teams-awarded-1m-to-advance-in-xprize-healthspan-101-million-race-to-transform-healthy-aging" ], "source_published_on": "2026-08-11", "freshness": "Current", "status": "Current program milestone · clinical evidence pending", "evidence_tracks": [ "Human outcomes", "Measures and endpoints", "Prevention interventions", "Science and market landscape" ], "source_facts": [ "XPRIZE announced 20 finalist teams in the XPRIZE Healthspan competition on August 11, 2026.", "XPRIZE identified 10 of the finalists as Milestone 2 Awardees receiving $1 million each.", "XPRIZE says finalists are expected to conduct coordinated clinical trials through 2029 involving adults aged 50 to 90 and measures of muscle, cognition, and immune function." ], "limits": [ "Finalist or milestone-award status is not evidence that a team or intervention is safe, effective, clinically beneficial, scalable, accessible, generalizable, or ready for use.", "The announcement does not establish regulatory authorization, endpoint validation, coverage, reimbursement, or favorable trial results.", "Team descriptions and future trial plans are attributed to the competition operator and should be updated when protocols, registries, results, peer-reviewed publications, or regulatory records become available." ], "p4l_interpretation": "The shared competition frame creates a useful watch set across interventions, endpoints, trial operations, accessibility, and evidence generation. Comparison should begin with protocols and results—not award status.", "decision_use": "Track each team by intervention class, registered protocol, population, comparator, endpoint validity, follow-up, harms, attrition, effect estimates, accessibility, and independent corroboration before drawing clinical or adoption conclusions.", "watch_conditions": [ "Trial registrations and protocols", "Endpoint definitions and validation evidence", "Enrollment, comparator, duration, attrition, and harms reporting", "Results, peer review, regulatory records, and independent replication", "Evidence supporting scalability and accessibility claims" ], "dependent_views": [ "/source-watch/", "/public-references/healthspan-evidence-map/", "/data/v2/query-index.json" ] } ] }